MA29403B1 - Forme cristalline d'un compose quinolinone-carboxamide - Google Patents

Forme cristalline d'un compose quinolinone-carboxamide

Info

Publication number
MA29403B1
MA29403B1 MA30317A MA30317A MA29403B1 MA 29403 B1 MA29403 B1 MA 29403B1 MA 30317 A MA30317 A MA 30317A MA 30317 A MA30317 A MA 30317A MA 29403 B1 MA29403 B1 MA 29403B1
Authority
MA
Morocco
Prior art keywords
forms
quinolinone
crystalline form
crystalline salt
carboxamide compound
Prior art date
Application number
MA30317A
Other languages
English (en)
French (fr)
Inventor
Paul R Fatheree
S Derek Turner
Adam Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA29403B1 publication Critical patent/MA29403B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA30317A 2005-04-06 2007-10-25 Forme cristalline d'un compose quinolinone-carboxamide MA29403B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
MA29403B1 true MA29403B1 (fr) 2008-04-01

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30317A MA29403B1 (fr) 2005-04-06 2007-10-25 Forme cristalline d'un compose quinolinone-carboxamide

Country Status (29)

Country Link
US (4) US7728004B2 (OSRAM)
EP (1) EP1874766B1 (OSRAM)
JP (2) JP5230407B2 (OSRAM)
KR (1) KR101322873B1 (OSRAM)
CN (1) CN101151264B (OSRAM)
AR (2) AR053208A1 (OSRAM)
AT (1) ATE479682T1 (OSRAM)
AU (1) AU2006232129B2 (OSRAM)
BR (1) BRPI0610657A2 (OSRAM)
CA (1) CA2603654C (OSRAM)
CY (1) CY1111275T1 (OSRAM)
DE (1) DE602006016586D1 (OSRAM)
DK (1) DK1874766T3 (OSRAM)
EA (1) EA012115B1 (OSRAM)
ES (1) ES2350495T3 (OSRAM)
HR (1) HRP20100629T1 (OSRAM)
IL (1) IL186023A (OSRAM)
MA (1) MA29403B1 (OSRAM)
MX (1) MX2007012438A (OSRAM)
MY (1) MY151075A (OSRAM)
NO (1) NO339699B1 (OSRAM)
NZ (1) NZ561900A (OSRAM)
PE (1) PE20061310A1 (OSRAM)
PL (1) PL1874766T3 (OSRAM)
PT (1) PT1874766E (OSRAM)
SI (1) SI1874766T1 (OSRAM)
TW (1) TWI377206B (OSRAM)
WO (1) WO2006108127A2 (OSRAM)
ZA (1) ZA200708071B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US20080287486A1 (en) * 2007-05-17 2008-11-20 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
NZ614151A (en) * 2007-12-07 2015-04-24 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
HUE038141T2 (hu) * 2009-04-13 2018-10-29 Theravance Biopharma R&D Ip Llc 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
SI3661518T1 (sl) * 2017-07-31 2025-01-31 Alfasigma S.P.A. Načini zdravljenja simptomov gastropareze z zdravilom velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
JP2025533507A (ja) 2022-09-20 2025-10-07 アルファシグマ ソシエタ ペル アチオニ 慢性偽性腸閉塞症（ｃｉｐｏ）の治療に使用するためのベルセトラグ

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
EP0670319A4 (en) 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
WO2005049608A1 (en) 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
JP2008530225A (ja) 2005-02-17 2008-08-07 セラヴァンス， インコーポレーテッド インダゾール−カルボキサミド化合物の結晶型
WO2006094063A1 (en) 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
NO20075574L (no) 2007-11-02
KR101322873B1 (ko) 2013-10-30
HRP20100629T1 (hr) 2010-12-31
PT1874766E (pt) 2010-11-30
JP5230407B2 (ja) 2013-07-10
BRPI0610657A2 (pt) 2010-07-13
CN101151264A (zh) 2008-03-26
EA200702161A1 (ru) 2008-04-28
EP1874766A2 (en) 2008-01-09
IL186023A (en) 2011-09-27
PL1874766T3 (pl) 2011-02-28
EA012115B1 (ru) 2009-08-28
EP1874766B1 (en) 2010-09-01
AR110019A2 (es) 2019-02-13
JP2012153725A (ja) 2012-08-16
IL186023A0 (en) 2008-01-20
TW200643020A (en) 2006-12-16
CA2603654A1 (en) 2006-10-12
ATE479682T1 (de) 2010-09-15
AU2006232129A1 (en) 2006-10-12
WO2006108127A3 (en) 2007-01-04
DE602006016586D1 (de) 2010-10-14
PE20061310A1 (es) 2007-01-23
US7728004B2 (en) 2010-06-01
US20160095849A1 (en) 2016-04-07
HK1110866A1 (en) 2008-07-25
US20100197728A1 (en) 2010-08-05
CA2603654C (en) 2014-05-27
US20140256769A1 (en) 2014-09-11
US9126994B2 (en) 2015-09-08
NZ561900A (en) 2010-12-24
NO339699B1 (no) 2017-01-23
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
AR053208A1 (es) 2007-04-25
WO2006108127A2 (en) 2006-10-12
TWI377206B (en) 2012-11-21
CN101151264B (zh) 2011-07-06
ZA200708071B (en) 2008-10-29
AU2006232129B2 (en) 2012-07-12
US20060229332A1 (en) 2006-10-12
CY1111275T1 (el) 2015-08-05
KR20070116988A (ko) 2007-12-11
DK1874766T3 (da) 2010-12-06
JP2008535848A (ja) 2008-09-04
SI1874766T1 (sl) 2010-12-31
ES2350495T3 (es) 2011-01-24
MY151075A (en) 2014-03-31
MX2007012438A (es) 2007-12-05

Similar Documents

Publication Publication Date Title
MA29403B1 (fr) Forme cristalline d&#39;un compose quinolinone-carboxamide
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
BR0314631A (pt) Derivados de pirrolidona como inibidores de maob
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
CA2534798A1 (en) Thiazole derivatives as cannabinoid receptor modulators
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
ATE496021T1 (de) Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
RU2012140182A (ru) (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA29909B1 (fr) Derives de pyridazine
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
TNSN01167A1 (fr) Formes de sels d&#39;amide d&#39;acide 3-(4-bromo-2,6-difluoro-benzyloxy) - 5 [3 - (4 - pyrrolidine - 1 - yl - butyl) ureido] isothiazole - 4 - carboxylique, et procede pour leur production.
FR2850576B1 (fr) Composition comprenant un melange de principes actifs, et procede de preparation
NO20041059L (no) Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens
WO2007066115A3 (en) Novel imaging agents for fibrosis
EP2664620A3 (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline form and processes
MA30554B1 (fr) Malates et formes polymorphes de l&#39;acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MA53427B1 (fr) Inhibiteurs de l&#39;arginase et leurs méthodes d&#39;utilisation
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
NO20090190L (no) Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
EP2945637B1 (en) Use of alpha 7 nicotinic acetylcholine receptor agonists